Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037164 · ClinicalTrials.gov registry record · Phase 3
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
A Phase 3 study of Anemia, sponsored by Cerus Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 692
- Enrollment target
- 16
- Study locations
NCT03037164: Active Phase 3 study of Anemia, sponsored by Cerus Corporation.
NCT03037164 is a Phase 3 study of Anemia that is active but no longer recruiting, run by Cerus Corporation. The registered enrollment target is 692 participants, above the 418-participant average among 72 other Anemia trials with a reported enrollment target (66% higher). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03037164, a Phase 3 study of Anemia, is active but no longer recruiting, sponsored by Cerus Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 692 participants
- Enrollment target
- 16
- Study locations
Study Summary
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
Primary Outcome
The difference between the pre-transfusion and post transfusion episode hemoglobin values divided by the total hemoglobin content transfused, averaged over one or more transfusion episodes in patients without active bleeding at baseline (active bleeding is defined as WHO Grade 3 or 4 bleeding)
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for Red Blood Cells
- DEVICE Conventional (Control)
Study Locations (16)
Other
- Menonita General Hospital - Aibonito
- HIMA San Pablo Hospital - Caguas
- San Juan Bautista School of Medicine Clinical Research Unit - Caguas
- Ege University Hospital - Izmir
Georgia
- Grady Health System - Atlanta
- CHOA (Children's Healthcare of Atlanta) - Atlanta
Texas
- UT Southwestern Medical Center - Dallas
- Baylor St. Luke's Medical Center - Houston
Arizona
- Phoenix Children's Hospital (PCH) - Phoenix
Connecticut
- Yale University - New Haven
Florida
- Mayo Clinic Jacksonville - Jacksonville
Maryland
- University of Maryland School of Medicine - Baltimore
Nevada
- C4TKs (Cure 4 The Kids) - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 3 |
What the registry record for NCT03037164 still lists
NCT03037164 is an interventional study that assigns participants to a tested intervention. The registered 692 participants enrollment target is mid-sized for trials with a published cap, above the 418-participant average among 72 other Anemia trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which INTERCEPT Blood System for Red Blood Cells is the first listed.
NCT03037164 lists 16 locations in 11 states (Other, Georgia, Texas).
Frequently Asked Questions
What is clinical trial NCT03037164 about?
NCT03037164 is a clinical study titled "INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections". To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
What is the current status of trial NCT03037164?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 692 participants. The study started on 2017-05-11. Estimated completion is 2026-12-30.
What conditions does trial NCT03037164 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT03037164?
The interventions under investigation include: INTERCEPT Blood System for Red Blood Cells (DEVICE), Conventional (Control) (DEVICE).
Who is sponsoring clinical trial NCT03037164?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03037164 being conducted?
This trial has 16 study locations across Arizona, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03037164's enrollment target sits among peer trials
692 11th of 72 higher than 62 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI